Beyond recurrence — a 47-year journey of long-term survival in Ewing's sarcoma with late complications

The prognosis for patients diagnosed with Ewing's sarcoma (EwS) substantially improved since the integration of chemotherapy (CHT) into treatment protocols in the early 1970s. In the preceding series, the 5-year overall survival rate was documented to be approximately 10%, while in the recent ones it ranges between 75% and 80%. Consequently, the reports of very long-term survivors (≥ 30 years post-treatment) are scarce, particularly in cases where secondary malignancies and pathological fractures are present. Therefore, we present the case of the longest (to our knowledge) survival in EwS reported to date. An 18-year-old female presented with a 10 × 7 × 7 cm tumor, which was identified as EwS following the biopsy. The tumor, located in the thigh, was associated with infiltration of lymph nodes and blood vessels. After surgical resection in September 1978, the patient received adjuvant CHT according to ROSEN protocol (dactinomicin, doxorubicin, cyclophosphamide and vincristine) and adjuvant radiotherapy (RT). The doses of CHT were adjusted due to grade 3–4 leukopenia. The patient completed adjuvant treatment by September 1980. In April 1980, doxorubicin was withdrawn upon reaching the cumulative dose of 775 mg. Despite complications including pathological fractures, the patient showed no evidence of disease recurrence on imaging follow-up. Over the years, the patient underwent several surgical procedures, including a mastectomy for ductal carcinoma in situ and resection for a basal cell adenoma of the hard palate. Throughout this period, regular follow-up imaging showed no recurrence or metastatic disease. As of early 2025, the patient remains alive with no evidence of disease progression or recurrence, marking a 47-year survival. The long-term bone sarcoma survivors require vigilant, lifelong screening and care, as they are at risk of relapse, secondary neoplasms and pathological fractures, particularly during certain biological events, including pregnancy.

Authors

Institutions

Publication Details

Journal
Oncology in Clinical Practice
Published
2025-10-07
DOI
https://doi.org/10.5603/ocp.108264
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond recurrence — a 47-year journey of long-term survival in Ewing's sarcoma with late complications

Anna Malgorzata Czarnecka, Maryna Rubach, Piotr Remiszewski
Oncology in Clinical Practice
Sarcoma Diagnosis and Treatment
article

Beyond recurrence — a 47-year journey of long-term survival in Ewing's sarcoma with late complications

Anna Malgorzata Czarnecka, Maryna Rubach, Piotr Remiszewski
article en

Abstract

The prognosis for patients diagnosed with Ewing's sarcoma (EwS) substantially improved since the integration of chemotherapy (CHT) into treatment protocols in the early 1970s. In the preceding series, the 5-year overall survival rate was documented to be approximately 10%, while in the recent ones it ranges between 75% and 80%. Consequently, the reports of very long-term survivors (≥ 30 years post-treatment) are scarce, particularly in cases where secondary malignancies and pathological fractures are present. Therefore, we present the case of the longest (to our knowledge) survival in EwS reported to date. An 18-year-old female presented with a 10 × 7 × 7 cm tumor, which was identified as EwS following the biopsy. The tumor, located in the thigh, was associated with infiltration of lymph nodes and blood vessels. After surgical resection in September 1978, the patient received adjuvant CHT according to ROSEN protocol (dactinomicin, doxorubicin, cyclophosphamide and vincristine) and adjuvant radiotherapy (RT). The doses of CHT were adjusted due to grade 3–4 leukopenia. The patient completed adjuvant treatment by September 1980. In April 1980, doxorubicin was withdrawn upon reaching the cumulative dose of 775 mg. Despite complications including pathological fractures, the patient showed no evidence of disease recurrence on imaging follow-up. Over the years, the patient underwent several surgical procedures, including a mastectomy for ductal carcinoma in situ and resection for a basal cell adenoma of the hard palate. Throughout this period, regular follow-up imaging showed no recurrence or metastatic disease. As of early 2025, the patient remains alive with no evidence of disease progression or recurrence, marking a 47-year survival. The long-term bone sarcoma survivors require vigilant, lifelong screening and care, as they are at risk of relapse, secondary neoplasms and pathological fractures, particularly during certain biological events, including pregnancy.

Oncology in Clinical PracticeVol. 22(0)
National Institute of Oncology (HU), The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Openalex Percentile: Top 59%
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.